Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer. In resectable gastric/gastroesophageal junction adenocarcinoma (GAC/GEJA) C, mismatch repair deficiency (dMMR)/microsatellite instability (MSI-H) can improve survival, and immunotherapy can avoid chemotherapy or surgery. The dMMR/MSI-H status is the strongest predictive biomarker for the benefit of immunotherapy with anti-programmed death receptor 1 and its ligands (PD-1/PD-L1) in advanced solid tumors, especially metastatic gastric/gastroesophageal junction adenocarcinoma. The INFINITY study provides Durvalumab combined with Tremelimumab as a treatment option with significant benefits for preoperative treatment of dMMR/MSI GAC/GEJAC, as well as the feasibility of non-surgical treatment strategies for such gastric cancer patients At present, there are no studies related to Asian gastric cancer patients, which are worthy of further verification and exploration in Asian gastric cancer cohorts.
Study Type
OBSERVATIONAL
Enrollment
12
Watching and Waiting in West China Hospital
Chengdu, Sichuan, China
Recurrence-free survival (RFS)
The recurrence-free survival time of gastric cancer patients
Time frame: One year, three years, or five years after the end of immunotherapy
Overall survival (OS)
The period from the start of randomization grouping in a clinical trial to the death of a patient for any cause
Time frame: One year, three years, or five years after the end of immunotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.